NCT06346392 2026-05-27AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2AstraZenecaPhase 3 Active not recruiting592 enrolled